Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent and/or metastatic head and neck cancer. Biological therapies such as gefitinib may interfere with the growth of tumor cells by blocking an enzyme necessary for cell growth.

Key facts

Study ID

NCT00024089

Run by

National Cancer Institute (NCI)

People needed

60

Starts

2001-07-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.